Acrongenomics, Inc., Molecular Vision Ltd. and Pearson Matthews Ltd., announce today that they have joined forces to design a fully-manufacturable, prototype, point-of-care medical diagnostic device suitable for detecting kidney and cardiac biomarkers.
Pearson Matthews Ltd., the design company has a reputation built around innovation and the development of breakthrough products. This will be the first time that the Molecular Vision technology has been designed into a prototype commercial product.
Chris Wright, Executive Chairman of Molecular Vision, stated, "Breaking through the micromolar detection limit is a significant achievement for Molecular Vision as it is thought to represent a world-first for the compact, low cost head-on geometry employed by Molecular Vision."
The basis for the device will be the proprietary Molecular Vision technology which uses organic light emitters and photodetectors, coupled with microfluidics for the detection of biomarkers in bodily fluids. The technology was first demonstrated to the public in March 2007. The diagnosis relies on the optical characterization of labelled biomarker molecules and can use fluorescence, absorption, chemiluminesence or any of the other usual optical detection methods.
Chris Wright, Executive Chairman of Molecular Vision, stated, "We are looking forward to working with Pearson Matthews and Acrongenomics on the development of our first commercial product. In combination, the three of us are able to provide innovative technology, product design and access to the market place."